Hannah Valantine, Director at BridgeBio Pharma, Inc. (BBIO), sold 8,140 shares at $44.03 ($358K) on 2025-06-26, disclosed to the SEC on 2025-06-30.
Open-market sale of $358k BBIO by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $44.01 | 1,542 | $68K | 18.9% |
| 2 | $44.01 | 1,542 | $68K | 18.9% |
| 3 | $44.03 | 1,891 | $83K | 23.2% |
| 4 | $44.03 | 1,891 | $83K | 23.2% |
| 5 | $44.11 | 876 | $39K | 10.8% |
| 6 | $44.13 | 398 |
| $18K |
| 4.9% |
| Total | $44.04 avg | 8,140 | $358K | 100% |
| Filing → |
| CDNA | SELL | 2026-06-16 | $280K | — | Filing → |
| BBIO | SELL | 2026-03-12 | $624K | — | Filing → |
| BBIO | SELL | 2026-03-03 | $1.7M | — | Filing → |